Table 3: Secondary outcomes.

OutcomeBaselineMean difference ± SE (95% CI) value2 yearsMean difference
± SE (95% CI)
valueTime by treatment interaction ( ; significance)

SF-36 PCS
 Active51.9 ± 19.211.8 ± 7.0 67.6 ± 16.330.5 ± 5.6
 Control39.7 ± 17.8(−2.2, 25.8) 0.137.1 ± 14.9(18.5, 42.6) <0.001* = 5.8;
SF-36 MCS
 Active64.7 ± 19.614.1 ± 7.273.7 ± 13.116.9 ± 4.8
 Control50.3 ± 19.7(−0.5, 28.6) 0.156.8 ± 12.5(7.2, 26.6) <0.001* = 0.032;
Knee Society Knee Score
 Active58.1 ± 18.83.4 ± 6.8 77.8 ± 12.117.8 ± 4.7
 Control54.1 ± 16.3(−10.3, 17.2) 0.660.0 ± 14.9(8.3, 27.3) <0.001* = 4.3;
Knee Society Function Score
 Active57.1 ± 16.08.5 ± 6.5 74.6 ± 18.325.2 ± 6.9
 Control47.2 ± 16.4(−4.6, 21.7) 0.249.4 ± 19.3(11.2, 39.0) <0.001* = 6.5;

SF-36: Short Form 36 (SF-36).
was considered statistically significant. Groups showed no significant differences at the baseline. Groups showed significant differences in all outcomes after two years. There was a significant difference in improvement over time between groups in all outcomes except for the SF-36 mental component summary (MCS).